Genetic risk factors associated with lipid-lowering drug-induced myopathies. - Wikidata - awgldk - TriplyDB

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

http://www.wikidata.org/entity/Q34521375

about

Genetic determinants of statin intolerance Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism The Interaction Between Statins and Exercise: Mechanisms and Strategies to Counter the Musculoskeletal Side Effects of This Combination Therapy Mitochondrial dysfunction in obesity: potential benefit and mechanism of Co-enzyme Q10 supplementation in metabolic syndrome Muscular effects of statins in the elderly female: a review Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis Overcoming Challenges With Statin Therapy Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle Polymorphisms in the mitochondrial ribosome recycling factor EF-G2mt/MEF2 compromise cell respiratory function and increase atorvastatin toxicity Pharmacogenomic insights into treatment and management of statin-induced myopathy.Metabolic disorders of purine metabolism affecting the nervous system.Rhabdomyolysis with simvastatin.Mechanisms and assessment of statin-related muscular adverse effects.Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies Special article: Future directions in malignant hyperthermia research and patient care Reversible dysphasia and statins.Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions Treatment Options for Statin-Associated Muscle Symptoms.Parsing interindividual drug variability: an emerging role for systems pharmacology.Statin-associated muscle-related adverse effects: a case series of 354 patients.Prevalence of musculoskeletal pain and statin use.Coenzyme Q10: is there a clinical role and a case for measurement?Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood.Molecular mechanisms of statin intolerance Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Intensive risk factor control in stroke prevention.Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series Statin myopathy as a metabolic muscle disease.Molecular basis for statin-induced muscle toxicity: implications and possibilities.Polypill: for Pollyanna.Intolerance to statins: mechanisms and management.Physicians' Experiences as Patients with Statin Side Effects: A Case Series Perspectives on Exertional Rhabdomyolysis.Pharmacogenomics and adverse drug reactions: the case of statins.Update on toxic myopathies.Towards companion diagnostics for the management of statin therapy.Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.Asymptomatic/pauci-symptomatic creatine kinase elevations (hyperckemia).

P2860

Q21245682-B79E9638-0A5F-4114-AC57-78AE8D14386C Q24320093-C60FE6CE-4239-431A-8355-0254530A5B8B Q24603957-C966D578-0995-4D59-ADCB-F4655C6B6AE3 Q26771168-247BCF38-9A93-4ABA-8C45-61D9D3E6806A Q27009336-74AD6F32-04A9-45B0-A51F-D8D6E9457DAA Q27023343-925CA031-A2E5-493A-9F3A-0780F4FF851E Q28070052-B53F41DD-D5DB-44CC-9139-EE8C4BDC6B5E Q28073319-DC076620-9A24-46BC-B55F-AC56394388B3 Q28083004-DB6D3C29-0EF7-4D04-BE53-B22FB5F82359 Q28469099-5F246739-95A6-4633-A1F2-461AB0F548BC Q28480419-CC99779D-8AA7-49BF-AF84-3C1DA606EC4A Q33600104-0C7E77B8-5BB0-4EBD-8663-45003A5D6521 Q34430614-51CEFB73-C9F1-47DA-AA34-0F58F0B42B46 Q34526546-33CD2C80-03A7-4D2C-B7F5-8C3C0F3113D9 Q34570995-E1EF3D31-948B-4012-8AE2-3E15F8E1E694 Q35209452-7E4CB49F-6E3E-49B9-9068-30AA36D43E54 Q35250678-D55F7987-2378-40D0-A317-FB6562B63DFD Q35859277-5627D46B-D4DC-448E-9D86-ABF79B268853 Q35915932-2A12ECA5-B0CB-4655-AEA3-B38B3899BA1A Q36294394-0A396E87-7ED4-45C9-A016-1CD4600FA368 Q36417380-DAAF6C92-24D0-4568-A328-6F73C0E8A6F3 Q36509301-581AAD09-F02E-43C2-8BFB-EB5F53D8E4E6 Q36841011-2AB7ABB5-F1EA-45AA-997D-A19F22F64364 Q36869671-5BEA592E-880F-4BD2-9AD3-01B0E4679D00 Q36923822-E4092CFE-C2F0-45FB-AB78-72F0EA2639AA Q36958324-A96E51E4-91A3-4931-BBCA-6BF9457F8F89 Q36986507-E0CE0F40-BDF6-43E6-8A58-9E92238F87E2 Q37215333-C46D9F0F-9134-4A72-A7F4-C9179F8A50C7 Q37218787-532D94F9-B279-47B8-9A97-F27AC2941FAA Q37230388-764CDD42-9C57-4391-BED3-010CF61F91C7 Q37235648-A0C97B4D-53A3-4E4A-A5DB-DCAF1950E6A3 Q37244546-F06791AB-1382-466E-A576-97EA7E605C07 Q37577161-AC200530-5E36-47EC-A586-43202C34E3B4 Q37651630-FEBE32DD-C07C-4708-843E-D21030881E2E Q37727522-FABED66B-6205-4304-945E-99998E7B0D32 Q37875115-5FBB647B-38D1-4EBE-8DA6-0AE3BE5680F4 Q37942033-17555207-1731-492F-A973-288AE0DC655A Q38089842-D4FC01BC-AE82-437F-920C-2C2FC1963B26 Q38092053-1934848C-2C5E-40F4-9DB5-3FEFE1BC8C26 Q38102654-CCFE3F63-396E-4CC5-A575-3EA19CF82571

P2860

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

http://www.wikidata.org/entity/Q34521375

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

@ast

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

@en

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

@nl

type

label

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

@ast

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

@en

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

@nl

prefLabel

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

@ast

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

@en

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

@nl

P1433

Q34521375-86B29223-602F-4070-822B-1E2D66584A9C

P1476

Q34521375-FF17E4CE-49C4-41B9-9D1F-D4E28E5936EE

P2093

Q34521375-14D711D2-B69E-45AA-88E8-06AEA81D0B29

Q34521375-5FEAD814-0661-4964-B050-60D0C991675F

Q34521375-699523B4-F806-4162-AF2A-F2AF0178E94E

Q34521375-AAE38A9F-F9BE-4B40-B8D7-CF4A13D3963C

Q34521375-B092DDBD-29C4-4335-8F03-59F6414A6489

Q34521375-B718D16C-C3FB-4073-8E2B-7D97AC56C87C

Q34521375-BF672A4A-1C93-4779-9F45-3C37D58FB3A8

Q34521375-C286C717-C186-4E0F-9FCD-BCE7F3579FF4

Q34521375-FEC56246-012E-495B-BFEF-5FE0D84E9EFF

P2860

Q34521375-174AA43F-98DA-474C-8A87-1CAB75CF8992

Q34521375-57463294-E677-4D19-8CDF-0087CB5E9C88

Q34521375-89D7A5AE-755C-41D4-8B59-6B8A08B991E3

Q34521375-A7709179-7209-45A6-A2CD-8FF606BD9B14

Q34521375-B4821219-F091-4A64-B51C-6D78D836E0FC

Q34521375-C0F139DC-8F44-46B6-824A-321B75D3D4CA

P304

Q34521375-8CC5CADA-9B0D-45DC-AE09-3DC5BFA2F32A

P31

Q34521375-1B6D7D89-1BFC-42B3-9950-8D0FBCD1B9FC

P356

Q34521375-25B74E71-A674-4029-992F-544D834EF42C

P433

Q34521375-F2BC750B-3FFB-4FBD-BF05-58C0992A50A1

P478

Q34521375-EEF62F3E-06D3-4C43-BEC7-42B5F817FBD9

P577

Q34521375-9AB29805-DE60-42B0-8624-91365DD7E435

P698

Q34521375-C66FFA44-CB76-4829-9D91-2EB48C458C3C

P356

P1433

Muscle and Nerve

P1476

Genetic risk factors associated with lipid-lowering drug-induced myopathies.

@en

P2093

Alexandru C Barboi

http://www.w3.org/2001/XMLSchema#string

Georgirene D Vladutiu

http://www.w3.org/2001/XMLSchema#string

Mark Tarnopolsky

http://www.w3.org/2001/XMLSchema#string

Naganand Sripathi

http://www.w3.org/2001/XMLSchema#string

Paul J Isackson

http://www.w3.org/2001/XMLSchema#string

Paul S Phillips

http://www.w3.org/2001/XMLSchema#string

Robert L Wortmann

http://www.w3.org/2001/XMLSchema#string

Wendy L Peltier

http://www.w3.org/2001/XMLSchema#string

Zachary Simmons

http://www.w3.org/2001/XMLSchema#string

P2860

Biochemical functions of coenzyme Q10

Statin-associated myopathy with normal creatine kinase levels.

Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.

PCR amplification of specific alleles: rapid detection of known mutations and polymorphisms.

Cerebellar ataxia and coenzyme Q10 deficiency.

Atorvastatin-induced polyneuropathy.

P304

153-162

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MUS.20567

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16671104

http://www.w3.org/2001/XMLSchema#string